Selank and Semax are two of the best-known peptides to emerge from Russian neuropharmacology research, both developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and both registered as prescription medicines in Russia. They are frequently discussed together because they share a small-peptide, blood-brain-barrier-penetrant design philosophy and a research history spanning several decades — yet their parent molecules, target systems, and primary research focus differ substantially. This article compares Selank and Semax mechanism by mechanism, summarizes the published research base for each, and lays out practical handling considerations, strictly for laboratory and research purposes. It builds on the foundational concepts introduced in our beginner’s guide to peptide research.
What Is Selank?
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide fragment of the immunoglobulin G heavy chain. Selank was engineered by extending the tuftsin sequence with a Pro-Gly-Pro tripeptide to resist rapid enzymatic degradation, dramatically extending its biological half-life relative to native tuftsin. Selank has been registered as an anxiolytic pharmaceutical in Russia since 2009 and is studied primarily in the context of anxiety, stress-response regulation, and mood. Reference material on handling and format is available at Selank 5mg.
What Is Semax?
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the adrenocorticotropic hormone fragment ACTH(4-10). Like Selank, it was designed with a Pro-Gly-Pro tail for proteolytic stability. Critically, Semax was engineered to retain the central-nervous-system activity of the ACTH fragment while dropping the melanocortin-receptor-mediated hormonal effects (adrenal steroidogenesis, pigmentation) associated with full-length ACTH. Semax has been studied and used in Russia since the 1990s, primarily in the context of cognitive performance, cerebrovascular recovery, and neuroprotection research. Reference material is available at Semax 5mg.
Mechanism of Action
Although both peptides are heptapeptides with a stabilizing Pro-Gly-Pro motif and both are described as crossing the blood-brain barrier after intranasal administration, their proposed mechanisms diverge substantially.
Selank’s proposed mechanisms:
- GABA-A receptor modulation. Selank is reported to enhance GABA-A receptor sensitivity to endogenous GABA without acting as a direct agonist itself — a mechanistically distinct profile from benzodiazepines, which may help explain reports of anxiolytic activity without the sedation, motor impairment, or dependence liability associated with classical benzodiazepine anxiolytics.
- Monoamine turnover. Preclinical work has reported changes in serotonin metabolism (altered 5-HIAA/serotonin ratios) in limbic and striatal regions following Selank administration, suggesting an additional serotonergic contribution to its studied anxiolytic profile.
- Neurotrophic and transcriptional effects. Transcriptomic studies have reported that a single dose of Selank alters expression of a substantial number of hippocampal genes, including some associated with GABAergic neurotransmission and neurotrophic signaling, within hours of administration.
- HPA-axis modulation. Selank is discussed in the literature as normalizing hypothalamic-pituitary-adrenal axis activity under stress, consistent with its tuftsin-derived immunomodulatory lineage.
Semax’s proposed mechanisms:
- Neurotrophin upregulation. Semax has been repeatedly reported to increase brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression, along with trkB receptor phosphorylation, in the hippocampus and basal forebrain — a mechanism proposed to underlie its studied cognitive and neuroprotective effects.
- Post-ischemic neurotrophin and immune-gene transcription. In rodent cerebral ischemia models, Semax has been reported to activate transcription of BDNF, NGF, NT-3, and their receptor genes at multiple timepoints after arterial occlusion, alongside modulation of immune- and vascular-related gene expression.
- Monoaminergic and opioid-peptide interactions. Semax is also discussed as interacting with dopaminergic, serotonergic, and enkephalinergic signaling, which may contribute to reported effects on attention and psychomotor performance distinct from its neurotrophic actions.
- Retention of central ACTH activity without adrenal effects. Because Semax lacks the C-terminal portion of full ACTH required for robust melanocortin-receptor-driven steroidogenesis, it is studied as a way to isolate CNS-relevant ACTH-fragment activity from systemic hormonal effects.
Research Background & Key Findings
Selank — clinical trial in generalized anxiety disorder and neurasthenia. Zozulya et al. (2008), published in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, reported a controlled clinical study of 62 patients with generalized anxiety disorder or neurasthenia, comparing intranasal Selank (1,350 mcg/day) against the benzodiazepine medazepam over 14 days. Both groups showed comparable reductions on the Hamilton Anxiety Rating Scale and Zung self-rating scale; the Selank group additionally showed anti-asthenic (anti-fatigue) improvements and mild psychostimulant-type effects not reported in the benzodiazepine group, without the sedation typically associated with benzodiazepine treatment.
Selank — gene expression in GABAergic neurotransmission. A study published in Frontiers in Pharmacology (2016) examined Selank’s effects on the expression of genes involved in GABAergic neurotransmission, reporting altered expression patterns consistent with a GABA-A receptor system-modulating mechanism, complementing earlier rodent transcriptome work from the same research group describing broad hippocampal gene-expression changes after a single Selank dose.
Semax — acute ischemic stroke. Gusev, Skvortsova, and colleagues (1997), published in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, reported a clinical and electrophysiological study of Semax (12–18 mg/day for 5–10 days) added to intensive stroke therapy in patients with acute hemispheric ischemic stroke, using clinical rating scales, EEG mapping, and somatosensory evoked potentials. The study reported that Semax was associated with accelerated restoration of neurological function, including motor deficits, relative to conventional therapy alone — an early and frequently cited human dataset for Semax in a defined clinical context.
Semax — BDNF/trkB signaling in the hippocampus and basal forebrain. Dolotov et al. (2006), published in the Journal of Neurochemistry, reported that Semax binds specifically and increases BDNF protein levels and trkB tyrosine phosphorylation in rat basal forebrain and hippocampus, with reported increases of up to roughly 1.4-fold in BDNF protein and up to 3-fold in exon-III BDNF mRNA after a single application — mechanistic support for the neurotrophic hypothesis underlying Semax’s studied cognitive effects.
Fold change vs. baseline after a single application in rat basal forebrain / hippocampus. Preclinical rodent data.
Semax — neurotrophin transcription after cerebral ischemia. Inozemtseva et al. (2009), published in Cellular and Molecular Neurobiology, reported that Semax (and the related tripeptide Pro-Gly-Pro) activated transcription of BDNF, TrkA, and TrkC at 3 hours post-occlusion, and NT-3 and NGF at 24 and 72 hours post-occlusion, respectively, in a rat cerebral ischemia model — supporting a time-dependent, multi-neurotrophin mechanism for Semax’s studied neuroprotective activity.
- 1
3 hours post-occlusion
Transcription of BDNF, TrkA, and TrkC activated.
- 2
24 hours post-occlusion
NT-3 transcription activated.
- 3
72 hours post-occlusion
NGF transcription activated.
Because Selank and Semax are almost always studied in separate trial programs and rodent models rather than head-to-head, and because a meaningful share of the underlying clinical literature originates from Russian-language journals with limited independent replication outside Russia, findings for both peptides should be treated as an evolving, preliminary evidence base rather than settled clinical fact — particularly regarding real-world human efficacy and long-term safety outside the studies cited above.
Comparison Table
| Selank | Semax | |
|---|---|---|
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro |
| Parent molecule | Tuftsin (immunoglobulin G-derived tetrapeptide) | ACTH(4-10) fragment of adrenocorticotropic hormone |
| Registered use (Russia) | Anxiolytic pharmaceutical (since 2009) | Nootropic/neuroprotective pharmaceutical (since the 1990s) |
| Primary research focus | Anxiety, stress response, mood, HPA-axis regulation | Cognition, attention, cerebrovascular recovery, neuroprotection |
| Proposed core mechanism | GABA-A receptor sensitivity modulation; serotonin turnover; hippocampal gene expression | BDNF/NGF/trkB upregulation; neurotrophin gene transcription; monoaminergic modulation |
| Key cited human data | Zozulya et al. 2008 (GAD/neurasthenia vs. medazepam) | Gusev et al. 1997 (acute ischemic stroke) |
| Key cited preclinical data | Frontiers in Pharmacology 2016 (GABAergic gene expression) | Dolotov et al. 2006 (BDNF/trkB); Inozemtseva et al. 2009 (post-ischemic neurotrophin transcription) |
| Hormonal (ACTH-type) activity | Not applicable (tuftsin-derived) | Designed to avoid adrenal/melanocortin-receptor steroidogenic activity |
| Typical research administration route | Intranasal (most cited studies) | Intranasal (most cited studies) |
Forms, Reconstitution & Handling
In laboratory settings, both Selank and Semax are commonly supplied as lyophilized (freeze-dried) powder in sealed vials for reconstitution prior to use in a study protocol. Reference material on commonly available vial strengths can be found at Selank 5mg and Semax 5mg.
General handling notes applicable to peptide research work with both compounds:
- Reconstitute gently — introduce bacteriostatic water (or sterile water, per protocol) along the inside wall of the vial rather than directly onto the lyophilized powder, and swirl rather than shake to minimize mechanical stress on the peptide.
- Maintain sterile technique: alcohol-swab stoppers before each access, use single-use needles, and use appropriately calibrated syringes for the small volumes typically involved with these compact heptapeptides.
- Record the reconstitution date, diluent, and final concentration clearly on the vial label to preserve an accurate laboratory record, since both peptides are commonly cited in intranasal-delivery research protocols where consistent concentration matters for dose-response interpretation.
Research Considerations
The following general considerations appear repeatedly in the published literature on Selank and Semax and are presented here for educational context, not as instructions for use:
- Route of administration. The majority of both the Russian clinical literature and rodent mechanistic studies for both peptides use intranasal delivery, reflecting their design intent to reach the CNS while limiting systemic (including hormonal) exposure.
- Short peptide half-life considerations. Both molecules were specifically engineered with a Pro-Gly-Pro C-terminal extension to resist peptidase degradation relative to their unmodified parent fragments (tuftsin and ACTH(4-10), respectively) — a design detail relevant to interpreting dosing frequency in the cited studies.
- Distinct but potentially complementary target systems. Because Selank’s most-cited mechanism centers on GABAergic/serotonergic and HPA-axis pathways while Semax’s centers on neurotrophin signaling, some research discussion frames them as addressing different axes of CNS function (anxiety/stress vs. cognition/neuroprotection) rather than as interchangeable or directly competing compounds.
- Evidence base is geographically concentrated. A substantial share of the clinical and mechanistic literature for both peptides originates from Russian research institutions and Russian-language journals; researchers evaluating this literature should weigh replication status and translation accuracy alongside study design when assessing evidence strength.
Storage & Stability
General cold-chain principles commonly cited for lyophilized research peptides of this class:
| Form | Typical Storage | Notes |
|---|---|---|
| Lyophilized (unreconstituted) | −20°C, extended stability (often cited as 1–2+ years) | Protect from light and moisture; avoid repeated freeze-thaw cycles |
| Reconstituted | 2–8°C (refrigerated) | Commonly cited stability window of several weeks; use a labeled, dated vial and discard per protocol expiry |
Always confirm specific storage parameters against the certificate of analysis (COA) or manufacturer documentation for the specific research lot in use, since excipients and reconstitution diluent can affect stability.
Safety, Legality & Research Disclaimers
Selank and Semax are registered pharmaceutical products in Russia but are not approved medicines in the European Union, the United States, or most other jurisdictions as of this writing. Both compounds discussed here are intended strictly for laboratory and research purposes — not for human or animal consumption, self-administration, or diagnostic/therapeutic use outside of a properly authorized research or clinical framework. Researchers are responsible for complying with all applicable EU, national, and institutional regulations regarding the acquisition, storage, and use of investigational peptides, including biosafety and chemical-handling rules. Nothing in this article constitutes medical advice, and no information presented anywhere on PeptiMap should be interpreted as a recommendation for human or animal use.
FAQ
Are Selank and Semax the same type of peptide? No. Both are synthetic heptapeptides with a stabilizing Pro-Gly-Pro tail, but they are derived from different parent molecules — Selank from tuftsin, an immunomodulatory tetrapeptide, and Semax from ACTH(4-10), a fragment of adrenocorticotropic hormone. Their proposed primary mechanisms (GABAergic/serotonergic modulation versus neurotrophin upregulation) are also distinct.
Which one has more clinical (human) data? Both have Russian clinical literature dating back to the late 1990s and 2000s. Semax’s most-cited human dataset involves acute ischemic stroke (Gusev et al., 1997), while Selank’s most-cited human dataset involves generalized anxiety disorder and neurasthenia (Zozulya et al., 2008). Neither has an extensive, independently replicated Western clinical trial base as of this writing.
Do Selank and Semax work through the same mechanism? Not primarily. Selank’s most-discussed mechanism centers on GABA-A receptor modulation and serotonin turnover, while Semax’s centers on BDNF/NGF/trkB neurotrophin signaling. Some transcriptomic studies of Selank do report effects that touch on neurotrophic gene expression, so the two mechanisms are not entirely non-overlapping, but they are not the same pathway.
Is either peptide a hormone? Semax is derived from a fragment of the hormone ACTH but was specifically engineered to avoid the adrenal/melanocortin-receptor-mediated hormonal (steroidogenic) activity of full-length ACTH. Selank is derived from tuftsin, an immunomodulatory peptide, not a classical endocrine hormone.
What administration route is most commonly studied? Intranasal administration is the route most frequently used in the published clinical and preclinical literature for both peptides, consistent with their design goal of reaching the central nervous system efficiently.
Where can I find dosing-guide reference material for these peptides? See the Selank 5mg and Semax 5mg reference pages, and our beginner’s guide to peptide research for general context on handling conventions used across the research peptide literature.
References
- Zozulya AA, Neznamov GG, Siuniakov TS, et al. “Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia.” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008.
- “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.” Frontiers in Pharmacology, 2016.
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. “Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study).” Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 1997.
- Dolotov OV, et al. “Semax, an analogue of adrenocorticotropin(4–10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.” Journal of Neurochemistry, 2006.
- Inozemtseva LS, et al. “Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia.” Cellular and Molecular Neurobiology, 2009.
This article is for educational and research purposes only. Selank and Semax are research compounds and, outside Russia, are not approved medicines for general human use. Nothing here constitutes medical advice.